BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 15990917)

  • 1. Prospects for p53-based cancer therapy.
    Stokłosa T; Gołab J
    Acta Biochim Pol; 2005; 52(2):321-8. PubMed ID: 15990917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural and functional basis for therapeutic modulation of p53 signaling.
    Bassett EA; Wang W; Rastinejad F; El-Deiry WS
    Clin Cancer Res; 2008 Oct; 14(20):6376-86. PubMed ID: 18927276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relevance of p53 protein and its mutations for novel strategies in cancer therapy].
    Müller P; Nenutil R; Vojtĕsek B
    Cas Lek Cesk; 2004; 143(5):313-7. PubMed ID: 15305766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New transcription factor-based cancer therapy. Gene therapy, cell lysis, reactivation of p53 are the new approaches].
    Wiman KG
    Lakartidningen; 1997 Sep; 94(38):3268-72. PubMed ID: 9379794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tumor suppressor gene p53: mechanisms of action in cell proliferation and death].
    Mendoza-Rodríguez CA; Cerbón MA
    Rev Invest Clin; 2001; 53(3):266-73. PubMed ID: 11496714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy.
    Wiman KG
    Adv Cancer Res; 2007; 97():321-38. PubMed ID: 17419952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene-specific mechanisms of p53 transcriptional control and prospects for cancer therapy.
    Resnick-Silverman L; Manfredi JJ
    J Cell Biochem; 2006 Oct; 99(3):679-89. PubMed ID: 16676359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
    Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
    J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P53 and induction of apoptosis as a target for anticancer therapy.
    Neubauer A; Thiede C; Huhn D; Wittig B
    Leukemia; 1996 Jul; 10 Suppl 3():S2-S4. PubMed ID: 8656696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [p53 as a molecular target for cancer therapy].
    Ishioka C; Osada M; Gamo M; Kanamaru R
    Gan To Kagaku Ryoho; 1997 Dec; 24(15):2207-12. PubMed ID: 9422063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 mutation heterogeneity in cancer.
    Soussi T; Lozano G
    Biochem Biophys Res Commun; 2005 Jun; 331(3):834-42. PubMed ID: 15865939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting p53 for enhanced radio- and chemo-sensitivity.
    Lu C; El-Deiry WS
    Apoptosis; 2009 Apr; 14(4):597-606. PubMed ID: 19259822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells.
    Puca R; Nardinocchi L; Givol D; D'Orazi G
    Oncogene; 2010 Aug; 29(31):4378-87. PubMed ID: 20514025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
    Willis A; Jung EJ; Wakefield T; Chen X
    Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of genetic instability by gain-of-function p53 cancer mutants.
    Xu Y
    Oncogene; 2008 Jun; 27(25):3501-7. PubMed ID: 18223686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The p53 tumour suppressor gene.
    Steele RJ; Thompson AM; Hall PA; Lane DP
    Br J Surg; 1998 Nov; 85(11):1460-7. PubMed ID: 9823903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function.
    Kokontis JM; Wagner AJ; O'Leary M; Liao S; Hay N
    Oncogene; 2001 Feb; 20(6):659-68. PubMed ID: 11313999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The p53 tumor suppressor gene and gene product.
    Levine AJ
    Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutants of the tumour suppressor p53 L1 loop as second-site suppressors for restoring DNA binding to oncogenic p53 mutations: structural and biochemical insights.
    Merabet A; Houlleberghs H; Maclagan K; Akanho E; Bui TT; Pagano B; Drake AF; Fraternali F; Nikolova PV
    Biochem J; 2010 Mar; 427(2):225-36. PubMed ID: 20113312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classic and novel roles of p53: prospects for anticancer therapy.
    Fuster JJ; Sanz-González SM; Moll UM; Andrés V
    Trends Mol Med; 2007 May; 13(5):192-9. PubMed ID: 17383232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.